Method Of Using A Transgenic Nonhuman Animal In An In Vivo Test Method (e.g., Drug Efficacy Tests, Etc.) Patents (Class 800/3)
  • Patent number: 10900018
    Abstract: The present invention is in the field of stem cell biology, in particular in the field of developmental and regenerative biology. The invention generally relates to a method of generating cells capable of differentiating to a multicellular organoid unit that morphologically and/or functionally resembles the terminal ductal-lobular unit. More precisely, said cells are generated by dissociating mammary epithelial tissue, thereby gaining cells and culturing said cells in presence of a compound which elevates cAMP levels in a collagen gel. Under said culturing conditions said cells form a multicellular organoid unit facilitating to obtain a breast stem cell by isolating a single cell from said multicellular organoid unit. The present invention also relates to enriching said cells and differentiating them to a multicellular organoid that morphologically and/or functionally resembles the terminal ductal-lobular unit and use of said cells or said multicellular organoid in testing a compound.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 26, 2021
    Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH)
    Inventors: Christina H. Scheel, Jelena R. Linnemann, Lisa K. Meixner, Haruko Miura
  • Patent number: 10899826
    Abstract: The present disclosure provides pharmaceutical compositions including a plurality of IgG2 anti-CGRP antagonist antibodies comprising a high content of particular IgG2 disulfide isomers, and methods of using the same.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: January 26, 2021
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Jason Bock, John Kim
  • Patent number: 10822604
    Abstract: The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: November 3, 2020
    Assignee: MORPHOSYS AG
    Inventors: Katja Siegers, Jan Van Den Brulle
  • Patent number: 10822618
    Abstract: Transgenic non-human animals, e.g., rodents, e.g., mice comprising genomic mutations that inactive all of the serpin1A genes and thus lack any functional serpinA1 genes. As a result of the genomic mutations, the animals express no hepatic or circulatory AAT protein. Also provided herein are cells and tissues derived from the transgenic mice.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: November 3, 2020
    Assignee: University of Massachusetts
    Inventors: Christian Mueller, Florie Borel
  • Patent number: 10792311
    Abstract: Methods are provided for stimulating ovarian preantral and antral follicles in a mammal.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 6, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Yuan Cheng, Aaron J. W. Hsueh, Yorino Sato
  • Patent number: 10765762
    Abstract: Provided herein, inter alia, are non-human animals comprising nucleic acid sequences encoding a C3 protein that comprises a human sequence as well as transgenic non-human animals comprising a C3 gene that is human in whole or in part as well as methods for using the same to screen for candidate therapeutic molecules to treat complement-related nephropathies. Also provided herein are methods for improving kidney function in an individual diagnosed with or thought to have a complement-related nephropathy.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 8, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kishor Devalaraja-Narashimha, Lori Morton, Yifan Luo, Cong Huang, Karolina Meagher, Sarah Casanova
  • Patent number: 10750723
    Abstract: A method of identifying individual zebrafish (Danio rerio), containing the steps of: observing a striped pattern for each of an anal fin and a caudal fin of each individual of two or more zebrafish in side view; determining characteristics of each individual from the observed striped pattern; and identifying each individual on the basis of the characteristics obtained.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 25, 2020
    Assignee: Kao Corporation
    Inventor: Takahiro Hasumura
  • Patent number: 10676518
    Abstract: The ?4?2 neuronal nicotinic acetylcholine receptor (nAChR) plays a crucial role in nicotine addiction. The invention studied the effect of subunit phosphorylation on ?4?2 nAChR function and expression, and eleven residues located in the M3-M4 cytoplasmic loop were mutated to alanine and aspartic acid. When nicotine was used as an agonist, four mutations exhibited a statistically significant hypersensitivity to nicotine (S438D, S469A, Y576A, and S589A). Additionally, two mutations (S516D and T536A) that displayed normal activation with ACh displayed remarkable reductions in sensitivity to nicotine. The invention provides a knock-in mutant construct for the development of a transgenic mouse line with reduced nicotine sensitivity to be used in future studies.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: June 9, 2020
    Assignee: University of Puerto Rico
    Inventors: Jose A Lasalde-Dominicci, Nilza M Biaggi-Labiosa, Emir Aviles-Pagan, Daniel Caballero-Rivera
  • Patent number: 10613079
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: April 7, 2020
    Assignee: Q-STATE BIOSCIENCES, INC.
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Patent number: 10493111
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: December 3, 2019
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Patent number: 10487146
    Abstract: Methods for diagnosing and treating conditions associated with life-threatening neurological complications are provided. The methods involve in some aspects the identification of oxLDL and LOX-1 as critical players in pregnant subjects and in some cases subjects having severe preeclampsia (early onset preeclampsia). Related products and kits are also provided.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: November 26, 2019
    Assignee: The University of Vermont and State Agricultural College
    Inventor: Marilyn J. Cipolla
  • Patent number: 10471107
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 12, 2019
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Patent number: 10426815
    Abstract: Embodiments described herein relates to compositions and methods of preventing and/or treating itch in a subject using a therapeutically effective amount of a MRG receptor antagonist. e.g., a tripeptide QWF. In one embodiment, the itch is a non-histamine mediated itch.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: October 1, 2019
    Assignee: The General Hospital Corporation
    Inventors: Ethan A. Lerner, Ehsan Azimi, Vemuri B. Reddy
  • Patent number: 10377990
    Abstract: The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: August 13, 2019
    Assignee: SIgma-Aldrich Co. LLC
    Inventors: Nan Lin, Joaquina Mascarenhas, Audrey Chang, David Onions, Henry George, Kevin Kayser
  • Patent number: 10345292
    Abstract: The following discloses mammalian cells lines that stably express functional nematode acetylcholine receptor subunits. The resulting expression of functional ion channels has been made possible by the stable co-expression of the chaperone protein, RIC3. These cell lines are extremely useful for the high throughput screening (HTS) of compounds, to identify new candidate parasiticidal, including nematocidal, active ingredients.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 9, 2019
    Assignees: BOEHRINGER INGELHEIM ANIMAL HEALTH INC., SANOFI
    Inventors: Lance Hammerland, Brenda Bondesen, Jean-Marie Chambard, Thierry Vermat, Werner Dittrich, Michel Partiseti, Qing Zhou-Liu, Cathy Cojean, Rachid Boukaiba, Eric Tagat
  • Patent number: 10314295
    Abstract: Provided is a non-human animal that is highly practical as a hyperuricenia model, the non-human animal being the following: (a) a non-human animal obtained by producing a primary chimeric non-human animal by transplantation of human hepatocytes to an immunodeficient non-human animal with liver dysfunction; and subsequently administering a purine base-containing substance to the primary chimeric non-human animal, or (b) a non-human animal obtained by producing a serially transplanted chimeric non-human animal via two steps, a first step being a step of producing a primary chimeric non-human animal by transplantation of human hepatocytes to an immunodeficient non-human animal with liver dysfunction, a second step being a step of transplanting the human hepatocytes grown in the body of the primary chimeric non-human animal to an immunodeficient non-human animal with liver dysfunction, the second step being performed one or more times; and subsequently administering a purine base-containing substance to the seri
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: June 11, 2019
    Assignee: PHOENIXBIO CO., LTD.
    Inventors: Masakazu Kakuni, Yumiko Iwasaki, Chise Mukaidani
  • Patent number: 10266585
    Abstract: Embodiments of the invention are directed to compositions and methods related to Tau oligomers and Tau oligomer specific antibodies and their use in detecting and/or treating traumatic brain injury or chronic traumatic encephalopathy.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: April 23, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERITY OF TEXAS SYSTEM
    Inventor: Rakez Kayed
  • Patent number: 10190136
    Abstract: Transgenic non-human animals, e.g., rodents, e.g., mice comprising genomic mutations that inactive all of the serpin1A genes and thus lack any functional serpinA1 genes. As a result of the genomic mutations, the animals express no hepatic or circulatory AAT protein. Also provided herein are cells and tissues derived from the transgenic mice.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: January 29, 2019
    Assignee: University of Massachusetts
    Inventors: Christian Mueller, Florie Borel
  • Patent number: 10155030
    Abstract: The present invention pertains to a dendritic cell-based vaccine against rh-?-Syn, ?-synuclein specific peptide antibodies and related vaccines, and methods of treating, preventing, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: December 18, 2018
    Assignee: University of South Florida
    Inventors: Chuanhai Cao, Xiaoyang Lin
  • Patent number: 10093620
    Abstract: Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 9, 2018
    Assignee: PELLFICURE PHARMACEUTICALS, INC.
    Inventors: Per Borgström, Adrian Chrastina, Veronique Therese Baron, Parisa Abedinpour
  • Patent number: 10023922
    Abstract: In some aspects, described herein is a DNA methylation reporter. In some aspects, the DNA methylation reporter comprises a promoter whose activity can be affected by exogenous methylation changes without being independently regulated by the DNA methylation machinery, operably linked to a DNA sequence that encodes a reporter molecule. In some embodiments the DNA methylation reporter comprises (i) a promoter derived from a mammalian imprinted gene promoter; and (ii) a sequence that encodes a reporter molecule that is detectable in individual mammalian cells, wherein the promoter is operably linked to the sequence that encodes the reporter molecule. Also described are nucleic acids that comprise the DNA methylation reporter, cells that have the DNA methylation reporter integrated into their genome, and non-human mammals comprising cells that have the DNA methylation reporter integrated into their genome.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: July 17, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Yonatan Stelzer, Rudolf Jaenisch
  • Patent number: 10010565
    Abstract: Methods are provided for stimulating ovarian preantral and antral follicles in a mammal.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: July 3, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Yuan Cheng, Aaron J. W. Hsueh, Yorino Sato
  • Patent number: 9986721
    Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: June 5, 2018
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Claude Auriault, Véronique Pancre, Yu-Chun Lone, Anthony Pajot, François Lemonnier
  • Patent number: 9945844
    Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: April 17, 2018
    Assignee: Howard Hughes Medical Institute
    Inventors: Loren Looger, Karel Svoboda, Douglas Kim, Rex Kerr
  • Patent number: 9894888
    Abstract: The present invention provides a transgenic mouse which comprises a deficiency for murine T lymphocytes, B lymphocytes and NK cells, a deficiency for murine MHC class I and MHC class II molecules, and a functional xenogenic SIRP? transgene. This mouse is useful for in vivo screening of various compounds, including immuno-therapeutic agents and vaccines. The said mouse is also useful for testing the in vivo metabolism of xenobiotic compounds.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: February 20, 2018
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvie Garcia, Malika Serra-Hassoun
  • Patent number: 9820475
    Abstract: The disclosure relates to genetically modified swine wherein at least one allele of a SIGLEC1 gene has been inactivated and/or at least one allele of a CD163 gene has been inactivated. Genetically modified swine having both alleles of the SIGLEC1 gene and/or both alleles CD 163 gene inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSV). Methods for producing such transgenic swine are also provided.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: November 21, 2017
    Assignee: The Curators of the University of Missouri
    Inventors: Randall S. Prather, Kevin D. Wells, Kristin M. Whitworth
  • Patent number: 9783801
    Abstract: The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: October 10, 2017
    Assignee: BerGenBio ASA
    Inventors: David Micklem, James Lorens
  • Patent number: 9717222
    Abstract: Provided is a gene in drosophila designated as dSLC5A1. This gene is responsible for taste independent nutrient sensing. Activation of neurons expressing this gene results in hunger behavior. Provided are compositions and methods for identifying agents that can interfere with hunger behavior.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: August 1, 2017
    Assignee: New York University
    Inventors: Greg Seong-Bae Suh, Monica Dus
  • Patent number: 9700024
    Abstract: A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: July 11, 2017
    Assignees: FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Masaru Okabe, Masahito Ikawa, Tadashi Kimura, Keiichi Kumasawa
  • Patent number: 9670264
    Abstract: Described herein are recombinant integral membrane proteins having multiple transmembrane domains that have been engineered to be less hydrophobic, through alteration of the amino acid sequence of the native protein, but retain the ability to bind their natural ligand. The decreased hydrophobicity of the described proteins makes them more water soluble than the native protein, which allows the described proteins to be expressed in bacteria in large quantities and isolated in the absence of membranes, all while retaining the ability to interact with known ligands.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: June 6, 2017
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Renyu Liu, Jeffery G Saven, Jose Manuel Perez-Aguilar, Felipe Matsunaga, Jin Xi
  • Patent number: 9662407
    Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: May 30, 2017
    Assignee: TRANSLATUM MEDICUS INC.
    Inventor: Shelley Romayne Boyd
  • Patent number: 9639660
    Abstract: Disclosed are data processing and analysis methods for gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in amplifying the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion” and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Of the 2,087 genes, 13 genes show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTS, and therefore are suitable for the normalization of universal genes having relatively low expression levels.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: May 2, 2017
    Assignees: REFERNCEBIOLABS, CO., LTD, GENCURIX, INC.
    Inventors: Young Kee Shin, Mi Jeong Kwon, En Sel Oh, Yong Ho In, Sang Seok Koh
  • Patent number: 9629348
    Abstract: The present invention relates to a vector construct, and more specifically to a vector construct comprising human hypoxia inducible factor ? gene. The present invention also relates to a transgenic animal or cell containing said vector construct which in the presence of an inducing agent expresses human hypoxia inducible factor ? gene causing hair growth suppression. The present invention further relates to use of this animal model for determining the efficacy of methods for suppressing or inducing hair growth and discover further molecules which regulate hair growth.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: April 25, 2017
    Assignee: MANNIN RESEARCH INC.
    Inventor: Susan E. Quaggin
  • Patent number: 9617548
    Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: April 11, 2017
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Universiteit Gent
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Patent number: 9606124
    Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: March 28, 2017
    Assignee: The Regents of the University of Michigan
    Inventors: Max S. Wicha, Christophe Ginestier
  • Patent number: 9568467
    Abstract: Identification and use of compounds which inhibit the expression or activity of micro-RNAs for preventing and/or attenuating ageing. An in vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin including (a) bringing at least one test compound in contact with a sample of fibroblasts, (b) measuring the expression or the activity of at least one microRNA chosen from miR-134 and miR-152 in said fibroblasts, and (c) selecting the compounds for which an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the expression or an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the activity of at least one microRNA is measured in the fibroblasts treated in (a) compared with the untreated fibroblasts.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: February 14, 2017
    Assignee: CHANEL PARFUMS BEAUTE
    Inventors: Eleonora Candi, Gerry Melino, Gaelle Saintigny, Christian Mahe
  • Patent number: 9568468
    Abstract: Described herein are methods and composition for identifying agents that modulate nerve regeneration in vivo in extended third instar (ETI) Drosophila larvae. The methods include the use of ETI Drosophila larvae having a structural or functional disruption in one or more neurons (e.g., motor neurons) to evaluate a nerve regeneration phenotype over an extended developmental time period in the presence or absence of a test agent.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 14, 2017
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Barry Ganetzky, Daniel L. Miller, Shannon L. Ballard
  • Patent number: 9532554
    Abstract: The present invention provides (1) a method for producing a non-human animal having a humanized liver, comprising transplanting human hepatic stem cells and/or hepatic progenitor cells and/or immature hepatocytes to a liver-damaged non-human animal to induce the differentiation of the cells into hepatocytes, (2) a non-human animal having a humanized liver, produced by the method, (3) a method for examining the pharmacokinetics and/or hepatotoxicity of a test substance, comprising using the animal, (4) a method for producing human hepatocytes, comprising transplanting human hepatic stem cells and/or hepatic progenitor cells and/or immature hepatocytes to a liver-damaged non-human animal to induce the differentiation of the cells into hepatocytes, and (5) a method for examining the pharmacokinetics and/or hepatotoxicity of a test substance, comprising using human hepatocytes produced by the method.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: January 3, 2017
    Assignee: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY
    Inventors: Hideki Taniguchi, Yun-Wen Zheng
  • Patent number: 9462793
    Abstract: The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: October 11, 2016
    Assignee: PROBIODRUG AG
    Inventors: Stephan Schilling, Torsten Hoffmann, Hans-Ulrich Demuth
  • Patent number: 9433651
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: September 6, 2016
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Patent number: 9422360
    Abstract: Provided is a porcine CD28 receptor molecule, which is: 1) a protein consisting of an amino acid sequence represented by SEQ ID NO:2, or 2) a protein derived from 1) by substitution, deletion or addition of one or several amino acids in the amino acid sequence represented by SEQ ID NO:2 and having equivalent activity with 1). Further provided is a gene for coding the porcine CD28 receptor, the nucleotide sequence of which is shown as SEQ ID NO:1. When the provided co-stimulating receptor CD28 is expressed specifically and highly in a T cell, the activation, proliferation and cell factor secretion activity of the T cell when stimulated by an antigen can be enhanced, thereby enhancing the acquired immune response of a host and enhancing the immune effect of a vaccine.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: August 23, 2016
    Assignee: Zhonghao Chenguang Research Institute of Chemical Industry Company Limited
    Inventors: Xun Suo, Xianyong Liu, Huali Su, Xinxin Zhao, Xiaoxi Huang
  • Patent number: 9388233
    Abstract: The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: July 12, 2016
    Inventor: Roland Buelow
  • Patent number: 9387263
    Abstract: Described is a transgenic mouse with two transgenes, each of which transgene comprises a DNA sequence encoding a dominant negative form of RbAp48 protein, wherein the expression of the dominant negative form of RbAp48 is spatially restricted to the forebrain by a CaM Kinase IIa promoter and wherein the expression of the dominant negative form of RbAp48 is controlled by tetracycline-controlled transcriptional activation. Also provided are methods for evaluating in the transgenic mouse the potential therapeutic effect of an agent for slowing, inhibiting or preventing age-related memory decline in a mammalian subject.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: July 12, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Scott A. Small, Ilias Pavlopoulos, Eric R. Kandel
  • Patent number: 9273364
    Abstract: An object of the present invention is to develop a new alternative splicing reporter system and to provide a method for detecting alternative splicing patterns in a mammalian multicellular organism more precisely, a method for identifying efficiently substances and gene regions that affect alternative splicing in a mammalian multicellular organism, and the like by utilizing the alternative splicing reporter system. Specifically, the present invention relates to a method for detecting alternative splicing in a mammalian multicellular organism, and a method for identifying substances and gene regions that affect alternative splicing in a mammalian multicellular organism, which use a DNA construct in which at least two different reporter genes are inserted into a specific gene that undergoes alternative splicing, or a combination of DNA constructs (a combination of at least two different DNA constructs) in which DNA construct a reporter gene is inserted into a specific gene that undergoes alternative splicing.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: March 1, 2016
    Assignee: Kyoto University
    Inventors: Masatoshi Hagiwara, Akihide Takeuchi
  • Patent number: 9259487
    Abstract: The present invention provides a non-human mammal deficient in the expression of prothymosin ? gene in the striatum and a screening method for a prophylactic/therapeutic drug for Huntington's disease and the like, which uses the animal.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: February 16, 2016
    Assignee: Nagasaki University
    Inventor: Hiroshi Ueda
  • Patent number: 9220243
    Abstract: The invention provides genetically altered fish of the family Cyprinidae, or genus Danio, including zebrafish (Danio rerio) and host cells from these animals, where the fish have been genetically altered to lack or have a modified gene related to lipid metabolism, for example, an ApoE, ApoAI and/or LDL-R gene. In another aspect, the invention is directed to drug design or discovery using the animal or cell models of the invention and/or wild type zebrafish, and by administering an altered diet and/or environment to the animal of invention. The invention also provides methods for screening for a compound capable of ameliorating or preventing or reversing: atherosclerosis; hyperlipidemia; lipoprotein oxidation; the accumulation of lipid in a blood vessel wall; vascular inflammation associated with lipid accumulation in a blood vessel wall; acute atherosclerosis-associated events; heart attack; stroke.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: December 29, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Yury Miller, Konstantin Stoletov, Richard Klemke
  • Patent number: 9221894
    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: December 29, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Naxin Tu, Cagan Gurer, Li-Hsien Wang, Sean Stevens, Andrew J. Murphy
  • Patent number: 9221891
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 29, 2015
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Patent number: 9177104
    Abstract: Apparatus and methods associated with detecting prostate cancer (CaP) in a magnetic resonance (MR) image of a prostate of a CaP patient are described. One example apparatus includes logics that acquire an image of a prostate, learn a weighted vector, detect salient features in the image of the prostate, and generate a heatmap that facilitates detecting CaP. An image acquisition logic acquires a T2 weighted MR image of a prostate. A learning logic learns a weighted vector based on a set of positive LBP descriptors and a set of negative LBP descriptors extracted from the image at multiple scales. A salient feature detection logic detects salient features in the image based on the weighted vector and a pixel-by-pixel weighted Hamming matching of the image. A prediction logic generates a statistical probability heatmap based on the weighted vector and the weighted Hamming matching of the image.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: November 3, 2015
    Inventors: Anant Madabhushi, Haibo Wang
  • Patent number: 9173383
    Abstract: Provided herein is a recombinant non-human mammal having an immune system including human immune cells and having a liver including human liver cells, and methods for producing the same. Also provided are methods of screening a compound for activity in treating hepatitis, comprising: administering a test compound to a recombinant non-human mammal as described herein; and then detecting the presence or absence of said activity in said mammal (e.g., by biochemical assay), said presence of said activity in said mammal indicating that said compound has activity in treating hepatitis. Methods of making fusion cells useful for the production of human monoclonal antibodies are also provided.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: November 3, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Lishan Su, Liguo Zhang, Michael Washburn